Araticum (Annona crassiflora) seed extract as a chemopreventive agent against prostate cancer: activation of extrinsic and intrinsic apoptotic pathways in a preclinical model.

Authors

Iara Lopes Lemos, Maria Josiane Macedo, Felipe Rabelo Santos, Bianca Barbosa Rezende, Fabio Montico, Valeria Helena Alves Cagnon, Mario Roberto Marostica Junior

Published in

Journal of molecular histology. Volume 57. Issue 4. Jun 13, 2026. Epub Jun 13, 2026.

Abstract

Prostate cancer (PCa) is among the most frequently diagnosed malignancies in aging men and remains a major public health concern, highlighting the need for effective and safe preventive strategies. Annona crassiflora Mart. seed extract (ASE) was evaluated using the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Animals were divided into control and ASE-treated groups evaluated from 8-12 to 12-16 weeks of age. Control groups received the vehicle (water containing 10% DMSO), whereas ASE-treated groups received 100 mg/kg body weight of ASE. The preservation of hepatic histoarchitecture and normal body weight gain demonstrated that ASE was well tolerated and did not show hepatotoxic effects. ASE treatment increased the frequency of healthy prostatic epithelium in early prostate lesions (predominantly low-grade prostatic intraepithelial neoplasia (LGPIN)) and late prostate lesions (high-grade prostatic intraepithelial neoplasia (HGPIN) and well-differentiated adenocarcinoma (WDAC)) of PCa. Furthermore, ASE reduced HGPIN incidence in the ASE 12-16 group, showing a lower incidence of WDAC. In addition, ASE reduced androgen receptor (AR) protein levels as well as cytoplasmic and nuclear AR localization in late prostate lesions (HGPIN and WDAC) of PCa. ASE also induced apoptosis through multiple pathways, including upregulation of BID, BAD, and BAX, activation of caspase-8, caspase-9, and caspase-3, and downregulation of BCL-2, BCL-xL, and MCL-1. Thus, ASE promotes a pro-apoptotic environment unfavorable to tumor survival. Taken together, these results reinforce the potential of ASE to modulate prostatic homeostasis, indicating a promising strategy with chemopreventive effects and potential as an adjuvant therapy against PCa.

PMID:
42287333
Bibliographic data and abstract were imported from PubMed on 26 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.